Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer (2010)

Peer-Reviewed Study · Non-Small Cell Lung Cancer Collaborative Group (Cochrane Database of Systematic Reviews 2010;2010(5):CD007309) · May 12, 2010

Non-Small Cell Lung Cancer Collaborative Group (Cochrane Database of Systematic Reviews 2010, 2010-05-12: Individual-patient-data meta-analysis of 16 RCTs and 2714 patients comparing chemotherapy plus supportive care with supportive care alone in advanced NSCLC. It reports a pooled hazard ratio of 0.77 and an absolute survival gain of 9% at 12 months (20% to 29%).

This meta-analysis of chemotherapy in the supportive care setting demonstrates that chemotherapy improves overall survival in all patients with advanced NSCLC.

Abstract (AUTHORS' CONCLUSIONS)

Non-Small Cell Lung Cancer Collaborative Group (Cochrane Database of Systematic Reviews 2010, 2010-05-12: Individual-patient-data meta-analysis of 16 RCTs and 2714 patients comparing chemotherapy plus supportive care with supportive care alone in advanced NSCLC. It reports a pooled hazard ratio of 0.77 and an absolute survival gain of 9% at 12 months (20% to 29%). Funder/support: internal sources only – Medical Research Council, UK; no external funding. Authors' declaration: 'No conflict of interest.' Drugs tested: platinum and non-platinum cytotoxic regimens; the review found no difference by drug class (P=0.63) and no drug maker is named. Comparator: supportive care alone. Quality of life 'could not be formally assessed'. Free full text PMC11380090. Study type: review.